Success Rate of New Business in United States

Document Sample
Success Rate of New Business in United States Powered By Docstoc
					Odyssey Thera Awarded Contract From the United States
Environmental Protection Agency
Tuesday June 22, 2010 - 08:10 AM EDT

Source: PRNewsWire News Releases
Author: Odyssey Thera, Inc.

Click here to read the original story

SAN RAMON Calif., June 22 /PRNewswire/ -- Odyssey Thera, Inc., a leader in cell-based drug discovery and
profiling technologies, announced today that it has been awarded a contract from the United States
Environmental Protection Agency (EPA) to utilize its technology platform to profile the toxic effects of
compounds in the agency's ToxCastâ ¢ program. The program's goal is to better define the potential impact
of chemicals on the environment and human health. Under the contract, Odyssey Thera is eligible to receive
more than $7 million in the first year and $34 million over a period of up to five years. The specific value of
the award will depend on the volume of testing required during the contract period. The business was awarded
to Odyssey Thera through a competitive process and reflects the company's expertise and proven ability to
engineer and utilize novel cellular assays to monitor chemical activities.

Odyssey Thera has engineered the world's largest collection of high-content assays based on contextual
Protein-fragment Complementation Assay (PCA) technology, and a supporting platform capable of capturing
and analyzing hundreds of thousands of microscopic images per day. A proprietary database, consisting of
detailed human cell response patterns for thousands of drugs and toxicants, powers the analysis of novel
chemical entities and potential environmental hazards. "ToxCast is an ideal application of Odyssey's
capabilities, and we are proud to have the opportunity to contribute to this important EPA initiative," said
John K. Westwick, Ph.D., CEO of Odyssey Thera. "Our participation in these efforts exemplifies our
commitment to improving human health. At the same time, it validates our business strategy of rapidly
expanding the applications of our technology platform and the scope of our chemical response database."

Odyssey has previously applied its validated platform to accelerate target and drug development with premier
pharmaceutical companies including Pfizer, Inc., Abbott Laboratories and Merck and Co. The EPA contract is
the second major development for Odyssey's chemical and target profiling business in recent months,
following the announcement in March of an alliance with Lonza.

About Odyssey Thera

Odyssey Thera, Inc. is a privately held drug discovery technology company focused on improving the success
rate of new therapeutic development. Odyssey Thera's proprietary technologies measure pathway activity
within living human cells. Odyssey Thera IP also covers the use of the technology in live animals, plants and
diagnostic applications. To learn more about Odyssey Thera, please visit

About the US EPA ToxCastâ ¢ Program

The EPA launched the ToxCastâ ¢ research program in 2007 to develop a cost-effective approach for
prioritizing the toxicity testing of thousands of chemicals in a short period of time. This new approach to
determining how toxic chemicals could impact human health uses cutting-edge bioassays to determine how
chemicals affect cellular functions. Â ToxCastâ ¢ will help the EPA determine conditions where
environmental exposures pose risks to human health. For more information, see

SOURCE Odyssey Thera, Inc.

Powered By: FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following terms and conditions.
Conference calls info supplied by OpenCompany
Fundamental data supplied by Morningstar
Stock quotes supplied by Telekurs USA


Shared By:
Description: Success Rate of New Business in United States document sample